NICE recommends Kymriah to the Cancer Drugs Fund due to remaining questions about evidence to support it, but believes those questions will be resolved.
Article Source: UK drug-pricing watchdog recommends Novartis CAR-T for leukemia in final draft guidance.
0 Comments